- Home
- LSTA vs SNTI Comparison
LSTA vs SNTI Comparison
Compare LSTA & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSTA
- SNTI
- Stock Information
- Founded
- LSTA 1980
- SNTI 2016
- Country
- LSTA United States
- SNTI United States
- Employees
- LSTA N/A
- SNTI N/A
- Industry
- LSTA Misc Health and Biotechnology Services
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- LSTA Health Care
- SNTI Health Care
- Exchange
- LSTA Nasdaq
- SNTI Nasdaq
- Market Cap
- LSTA 20.0M
- SNTI 17.8M
- IPO Year
- LSTA N/A
- SNTI N/A
- Fundamental
- Price
- LSTA $2.07
- SNTI $3.21
- Analyst Decision
- LSTA Strong Buy
- SNTI Strong Buy
- Analyst Count
- LSTA 1
- SNTI 1
- Target Price
- LSTA $15.00
- SNTI $12.00
- AVG Volume (30 Days)
- LSTA 9.1K
- SNTI 25.4K
- Earning Date
- LSTA 05-08-2025
- SNTI 05-08-2025
- Dividend Yield
- LSTA N/A
- SNTI N/A
- EPS Growth
- LSTA N/A
- SNTI N/A
- EPS
- LSTA N/A
- SNTI N/A
- Revenue
- LSTA $1,000,000.00
- SNTI N/A
- Revenue This Year
- LSTA N/A
- SNTI N/A
- Revenue Next Year
- LSTA N/A
- SNTI N/A
- P/E Ratio
- LSTA N/A
- SNTI N/A
- Revenue Growth
- LSTA N/A
- SNTI N/A
- 52 Week Low
- LSTA $2.05
- SNTI $1.52
- 52 Week High
- LSTA $4.20
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- LSTA 34.86
- SNTI 40.87
- Support Level
- LSTA $2.31
- SNTI $3.20
- Resistance Level
- LSTA $2.46
- SNTI $3.63
- Average True Range (ATR)
- LSTA 0.15
- SNTI 0.35
- MACD
- LSTA -0.01
- SNTI -0.01
- Stochastic Oscillator
- LSTA 0.00
- SNTI 16.96
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.